Tag: Catalysts

Mamelodi catalysts for change awarded prizes for innovative business ideas

By Chelsea Ntuli Time of article published18m ago

Share this article:

Pretoria – Innovative business ideas by entrepreneurs that can have a positive impact on Mamelodi residents were awarded prizes that would allow them to continue to change lives in their communities.

As part of Ranyaka Community Transformation’s Proud of my town building business programme in Mamelodi, four winners were selected for identifying problems in their communities and coming up with solutions.

Ranyaka Community Transformation executive director and urban planner Maggie Tsotetsi said they were required to explain how they were going to generate money out of that concept.

The first prize winner was Given Maboela whose idea was to install affordable uncapped Wi-Fi access points to certain areas in the community.

He said his dream was to develop his very own internet service provider in rural areas especially in schools where they can have access

Read More

Delta Apparel Is At The Start Of A Significant Positive Inflection, With Near-Term Catalysts (NYSEMKT:DLA)

Editor’s note: Seeking Alpha is proud to welcome Analystman as a new contributor. It’s easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more »


I believe Delta Apparel, Inc. (DLA) will increase dramatically, with upside potential of $45+, due to imminent catalysts and the stock’s tremendous undervaluation. There are also many catalysts that I expect to drive an upward revaluation, most imminently DLA’s next earnings report (expected in November) which I project to be tremendously above consensus (one analyst) expectations. There has been the perfect storm of positive events that have occurred for DLA, yet the stock has barely reacted, and is near multi-year lows.

DLA is a high-growth technology and apparel company being undervalued by the market, because it is a small-cap in the apparel retail sector.

Read More

Catalyst Pharmaceuticals Looks Cheap, but Few Catalysts for Massive Upside

Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit. Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) has been one of those companies, but expectations also have been tempered.

Catalyst’s Firdapse is approved as a treatment for Lambert-Eaton myasthenic syndrome in those who are 17 years of age or older. This syndrome is a rare autoimmune neuromuscular disorder, and its U.S. population is estimated to be 1 in 100,000 people. Catalyst just started generating its revenues in 2019, and investors are trying to figure out if there are other drivers after earnings.

a close up of a bottle

© Provided by 24/7 Wall St.

Firdapse’s net revenues of $29.6 million in its second quarter seemed to indicate a slower decline than what had been feared. There also were improvements in the 90-day discontinuation rate.


Load Error

One key driver for the August disappointment

Read More